Simple Synthesis of [18F] AV-45 and its Clinical Application in the Diagnosis of Alzheimer's Disease


Cite item

Full Text

Abstract

Objective:[18F] AV-45 can be produced in a simple, stable, and repeatable manner on the Tracerlab FXF-N platform using a self-editing synthetic procedure and solid-phase extraction purification method. This technique is applied to positron emission tomography (PET) imaging of Alzheimer's disease (AD) to observe its distribution and characteristics in various brain regions and its diagnostic efficiency for the disease.

Methods:The precursor was subjected to nucleophilic radiofluorination at 120 °C in anhydrous dimethyl sulfoxide, followed by acid hydrolysis of the protecting groups. The neutralized reaction mixture was purified by solid phase extraction to obtain a relatively pure [18F] AV-45 product with a high specific activity. A total of 10 participants who were diagnosed with Alzheimer's disease (AD group) and 10 healthy controls (HC group) were included retrospectively. All of them underwent [18F] AV-45 brain PET/CT imaging. The distribution of [18F] AV-45 in the AD group was analyzed visually and semi-quantitatively.

Results:Six consecutive radiochemical syntheses were performed in this experiment. The average production time of [18F] AV-45 was 52 minutes, the radiochemical yield was 14.2 % ± 2.7% (n = 6), and the radiochemical purity was greater than 95%. When used with PET/CT imaging, the results of the visual analysis indicated increased [18F] AV-45 radioactivity uptake in the frontal, temporal, and parietal lobes in AD patients. Semiquantitative analysis showed the highest diagnostic efficacy in the posterior cingulate gyrus compared with other brain regions (p < 0.001).

Conclusion:Intravenous [18F] AV-45 was successfully prepared on the Tracerlab FXF-N platform by solid-phase extraction of crude product and automated radiochemical synthesis. PET/CT imaging can be used to diagnose and evaluate AD patients and provide a more robust basis for clinicians to diagnose AD.

About the authors

Qi-Zhou Zhang

Department of Nuclear Medicine, The First Affiliated Hospital of Xinjiang Medical University

Email: info@benthamscience.net

Nazi Yilihamu

Department of Nuclear Medicine, The First Affiliated Hospital of Xinjiang Medical University

Email: info@benthamscience.net

Yu-Bin Li

Department of Nuclear Medicine, The First Affiliated Hospital of Xinjiang Medical University

Email: info@benthamscience.net

Xiao-Hong Li

Department of Nuclear Medicine, The First Affiliated Hospital of Xinjiang Medical University

Email: info@benthamscience.net

Yong-De Qin

Department of Nuclear Medicine, The First Affiliated Hospital of Xinjiang Medical University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Weidner, W.S.; Barbarino, P. Thestate of the art of dementia research: New frontiers. Alzheimers Dement., 2019, 15(7), P1473. doi: 10.1016/j.jalz.2019.06.4115
  2. Zhang, Y.L.; Hu, X.L.; Li, Y.H.; Zhao, C.X. International clinical practice guideline of Chinese medicine Alzheimer. World J. Tradit. Chin. Med., 2021, 7, 265-275.
  3. Levin, O.S.; Vasenina, E.E. 25 Years of the amyloid hypothesis of the origin of Alzheimer’s disease: Advances, failures, and new perspectives. Neurosci. Behav. Physiol., 2017, 47(9), 1065-1070. doi: 10.1007/s11055-017-0513-0
  4. Litvinenko, I.V.; Emelin, A.Y.; Lobzin, V.Y. he amyloid hypothesis of Alzheimer’s disease: Past and present, hopes and disappointments. Neurology neuropsychiatry. Psychosomatics, 2019, 11(3), 4-10.
  5. Rinne, J.O.; Brooks, D.J.; Rossor, M.N.; Fox, N.C.; Bullock, R.; Klunk, W.E.; Mathis, C.A.; Blennow, K.; Barakos, J.; Okello, A.A.; de LIano, S.R.M.; Liu, E.; Koller, M.; Gregg, K.M.; Schenk, D.; Black, R.; Grundman, M. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: A phase 2, double-blind, placebo- controlled, ascending-dose study. Lancet Neurol., 2010, 9(4), 363-372. doi: 10.1016/S1474-4422(10)70043-0 PMID: 20189881
  6. Liu, E.; Schmidt, M.E.; Margolin, R.; Sperling, R.; Koeppe, R.; Mason, N.S.; Klunk, W.E.; Mathis, C.A.; Salloway, S.; Fox, N.C.; Hill, D.L.; Les, A.S.; Collins, P.; Gregg, K.M.; Di, J.; Lu, Y.; Tudor, I.C.; Wyman, B.T.; Booth, K.; Broome, S.; Yuen, E.; Grundman, M.; Brashear, H.R. Amyloid-β11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology, 2015, 85(8), 692-700. doi: 10.1212/WNL.0000000000001877 PMID: 26208959
  7. Koole, M.; Lewis, D.M.; Buckley, C.; Nelissen, N.; Vandenbulcke, M.; Brooks, D.J.; Vandenberghe, R.; Van Laere, K. Whole-body biodistribution and radiation dosimetry of 18F-GE067: A radioligand for in vivo brain amyloid imaging. J. Nucl. Med., 2009, 50(5), 818-822. doi: 10.2967/jnumed.108.060756 PMID: 19372469
  8. Snellman, A.; Rokka, J.; López-Picón, F.R.; Eskola, O.; Salmona, M.; Forloni, G.; Scheinin, M.; Solin, O.; Rinne, J.O.; Haaparanta-Solin, M. In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer’s disease with a high specific activity PET imaging agent 18Fflutemetamol. EJNMMI Res., 2014, 4(1), 37. doi: 10.1186/s13550-014-0037-3 PMID: 25977876
  9. Sabri, O.; Sabbagh, M.N.; Seibyl, J.; Barthel, H.; Akatsu, H.; Ouchi, Y.; Senda, K.; Murayama, S.; Ishii, K.; Takao, M.; Beach, T.G.; Rowe, C.C.; Leverenz, J.B.; Ghetti, B.; Ironside, J.W.; Catafau, A.M.; Stephens, A.W.; Mueller, A.; Koglin, N.; Hoffmann, A.; Roth, K.; Reininger, C.; Schulz-Schaeffer, W.J. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: Phase 3 study. Alzheimers Dement., 2015, 11(8), 964-974. doi: 10.1016/j.jalz.2015.02.004 PMID: 25824567
  10. Devous, M.D., Sr; Fleisher, A.S.; Pontecorvo, M.J.; Lu, M.; Siderowf, A.; Navitsky, M.; Kennedy, I.; Southekal, S.; Harris, T.S.; Mintun, M.A. Relationships between cognition and neuropathological tau in Alzheimer’s disease assessed by 18F flortaucipir PET. J. Alzheimers Dis., 2021, 80(3), 1091-1104. doi: 10.3233/JAD-200808 PMID: 33682705
  11. Chandra, A.; Valkimadi, P.E.; Pagano, G.; Cousins, O.; Dervenoulas, G.; Politis, M. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer’s disease and mild cognitive impairment. Hum. Brain Mapp., 2019, 40(18), 5424-5442. doi: 10.1002/hbm.24782 PMID: 31520513
  12. Nakamura, T.; Iwata, A.; Ueda, K.; Namiki, C. Clinical implications and appropriate use of amyloid imaging with florbetapir (18F) in diagnosis of patients with Alzheimer disease. Brain Nerve, 2016, 68(10), 1215-1222. PMID: 27703109
  13. Asghar, M.; Hinz, R.; Herholz, K.; Carter, S.F. Dual-phase 18Fflorbetapir in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging, 2019, 46(2), 304-311. doi: 10.1007/s00259-018-4238-2 PMID: 30569187
  14. Soffers, F.; Ceyssens, S.; Buffet, W.; de Surgeloose, D.; Crols, R. 18F-florbetapir PET in primary cerebral amyloidoma. Clin. Nucl. Med., 2020, 45(10), 838-839. doi: 10.1097/RLU.0000000000003214 PMID: 32796236
  15. Bateman, R.J.; Xiong, C.; Benzinger, T.L.S.; Fagan, A.M.; Goate, A.; Fox, N.C.; Marcus, D.S.; Cairns, N.J.; Xie, X.; Blazey, T.M.; Holtzman, D.M.; Santacruz, A.; Buckles, V.; Oliver, A.; Moulder, K.; Aisen, P.S.; Ghetti, B.; Klunk, W.E.; McDade, E.; Martins, R.N.; Masters, C.L.; Mayeux, R.; Ringman, J.M.; Rossor, M.N.; Schofield, P.R.; Sperling, R.A.; Salloway, S.; Morris, J.C. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med., 2012, 367(9), 795-804. doi: 10.1056/NEJMoa1202753 PMID: 22784036
  16. Fleisher, A.S.; Chen, K.; Quiroz, Y.T.; Jakimovich, L.J.; Gutierrez Gomez, M.; Langois, C.M.; Langbaum, J.B.S.; Roontiva, A.; Thiyyagura, P.; Lee, W.; Ayutyanont, N.; Lopez, L.; Moreno, S.; Muñoz, C.; Tirado, V.; Acosta-Baena, N.; Fagan, A.M.; Giraldo, M.; Garcia, G.; Huentelman, M.J.; Tariot, P.N.; Lopera, F.; Reiman, E.M. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: A cross-sectional study. JAMA Neurol., 2015, 72(3), 316-324. doi: 10.1001/jamaneurol.2014.3314 PMID: 25580592
  17. Donohue, M.C.; Jacqmin-Gadda, H.; Le Goff, M.; Thomas, R.G.; Raman, R.; Gamst, A.C.; Beckett, L.A.; Jack, C.R., Jr; Weiner, M.W.; Dartigues, J.F.; Aisen, P.S. Estimating long-term multivariate progression from short-term data. Alzheimers Dement., 2014, 10(5S)(Suppl.), S400-S410. doi: 10.1016/j.jalz.2013.10.003 PMID: 24656849
  18. Young, A.L.; Oxtoby, N.P.; Daga, P.; Cash, D.M.; Fox, N.C.; Ourselin, S.; Schott, J.M.; Alexander, D.C. A data- driven model of biomarker changes in sporadic Alzheimer’s disease. Brain, 2014, 137(9), 2564-2577. doi: 10.1093/brain/awu176 PMID: 25012224
  19. Xiong, C.; Jasielec, M.S.; Weng, H.; Fagan, A.M.; Benzinger, T.L.S.; Head, D.; Hassenstab, J.; Grant, E.; Sutphen, C.L.; Buckles, V.; Moulder, K.L.; Morris, J.C. Longitudinal relationships among biomarkers for Alzheimer disease in the adult children study. Neurology, 2016, 86(16), 1499-1506. doi: 10.1212/WNL.0000000000002593 PMID: 27009258
  20. Jack, C.R., Jr; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; Liu, E.; Molinuevo, J.L.; Montine, T.; Phelps, C.; Rankin, K.P.; Rowe, C.C.; Scheltens, P.; Siemers, E.; Snyder, H.M.; Sperling, R.; Elliott, C.; Masliah, E.; Ryan, L.; Silverberg, N. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement., 2018, 14(4), 535-562. doi: 10.1016/j.jalz.2018.02.018 PMID: 29653606
  21. Ismail, Z.; Black, S.E.; Camicioli, R.; Chertkow, H.; Herrmann, N.; Laforce, R., Jr; Montero-Odasso, M.; Rockwood, K.; Rosa-Neto, P.; Seitz, D.; Sivananthan, S.; Smith, E.E.; Soucy, J.P.; Vedel, I.; Gauthier, S. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Alzheimers Dement., 2020, 16(8), 1182-1195. doi: 10.1002/alz.12105 PMID: 32725777
  22. Lee, J.S.; Kim, G.H.; Kim, H.J.; Kim, H.J.; Na, S.; Park, K.H.; Park, Y.H.; Suh, J. Shin, J.H.; Oh, S.I.; Yoon, B. Clinical practice guideline for dementia (diagnosis and evaluation): 2021 revised edition. Dement Neurocogn. Disord., 2022, 21(1), 42-44.
  23. Shiino, A.; Shirakashi, Y.; Ishida, M.; Tanigaki, K. Machine learning of brain structural biomarkers for Alzheimer’s disease (AD) diagnosis, prediction of disease progression, and amyloid beta deposition in the Japanese population. Alzheimers Dement. (Amst.), 2021, 13(1), e12246. doi: 10.1002/dad2.12246 PMID: 34692983
  24. Spencer, B.E.; Jennings, R.G.; Brewer, J.B. Combined biomarker prognosis of mild cognitive impairment: An 11-year follow-up study in the Alzheimer’s disease neuroimaging initiative. J. Alzheimers Dis., 2019, 68(4), 1549-1559. doi: 10.3233/JAD-181243 PMID: 30958366
  25. Writing Goup of the Dementia and Cognitive Society of Neurology Committee of Chinese Medical Association. Guidelines for dementia and cognitive impairment in China: The diagnosis and treatment of mild cognitive impairment Zhonghua Yi Xue Za Zhi, 2018, 98(13), 7.
  26. Morris, E.; Chalkidou, A.; Hammers, A.; Peacock, J.; Summers, J.; Keevil, S. Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(2), 374-385. doi: 10.1007/s00259-015-3228-x PMID: 26613792
  27. Zhang, C.; Wang, C.; Xin, M. Value of visual analysis and SUVR during ^18F-AV45 PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer′s disease. Chin. J. Nucl. Med. Mol. Imaging, 2020, 40(4), 201-206.
  28. Zhang, L.; Zhang, A.; Yao, X.; Zhang, Y.; Liu, F.; Hong, H.; Zha, Z.; Liu, Y.; Wu, Z.; Qiao, J.; Zhu, L.; Kung, H.F. An improved preparation of 18FAV-45 by simplified solid-phase extraction purification. J. Labelled Comp. Radiopharm., 2020, 63(3), 108-118. doi: 10.1002/jlcr.3813 PMID: 31697847
  29. Zhang, Q.Z.; Li, Y.B.; Yilihamu, N.; Li, X.H.; Ba, Y.; Qin, Y.D. Optimization of automatic synthesis and separation of 18F AV-45 and quality control. Front Chem., 2022, 10, 826678. doi: 10.3389/fchem.2022.826678 PMID: 35494660
  30. Han, P.; Shi, J. A theoretical analysis of the synergy of amyloid and tau in Alzheimer’s disease. J. Alzheimers Dis., 2016, 52(4), 1461-1470. doi: 10.3233/JAD-151206 PMID: 27104897
  31. Zhu, Z.; Zhu, H. Research progress in imaging agents targeting Aβ and Tau protein in Alzheimer’s disease Z. Chin J Nucl Med Mol Imaging, 2018, 38(4), 291-294.
  32. Trembath, L.; Newell, M.; Devous, M.D., Sr Technical considerations in brain amyloid PET imaging with 18 F-florbetapir. J. Nucl. Med. Technol., 2015, 43(3), 175-184. doi: 10.2967/jnmt.115.156679 PMID: 26271806
  33. Veitch, D.P.; Weiner, M.W.; Aisen, P.S.; Beckett, L.A.; DeCarli, C.; Green, R.C.; Harvey, D.; Jack, C.R., Jr; Jagust, W.; Landau, S.M.; Morris, J.C.; Okonkwo, O.; Perrin, R.J.; Petersen, R.C.; Rivera-Mindt, M.; Saykin, A.J.; Shaw, L.M.; Toga, A.W.; Tosun, D.; Trojanowski, J.Q. Using the Alzheimer’s disease neuroimaging initiative to improve early detection, diagnosis, and treatment of Alzheimer’s disease. Alzheimers Dement., 2022, 18(4), 824-857. doi: 10.1002/alz.12422 PMID: 34581485
  34. Mukherjee, S.; Mez, J.; Trittschuh, E.H.; Saykin, A.J.; Gibbons, L.E.; Fardo, D.W.; Wessels, M.; Bauman, J.; Moore, M.; Choi, S.E.; Gross, A.L.; Rich, J.; Louden, D.K.N.; Sanders, R.E.; Grabowski, T.J.; Bird, T.D.; McCurry, S.M.; Snitz, B.E.; Kamboh, M.I.; Lopez, O.L.; De Jager, P.L.; Bennett, D.A.; Keene, C.D.; Larson, E.B.; Crane, P.K. Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups. Mol. Psychiatry, 2020, 25(11), 2942-2951. doi: 10.1038/s41380-018-0298-8 PMID: 30514930

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers